Capricor presents new data from HOPE-3 OLE study of deramiocel for DMD at WMS congress

Capricor Therapeutics presented new data from its ongoing HOPE-3 open-label extension study of lead asset deramiocel for treating upper limb impairment in Duchenne muscular dystrophy at the 31st Annual Congress of the World Muscle Society in Hiroshima.

Detected & updated continuously · Source: Nebula